Longitudinal multimodal biomarker studies reveal that the continuum of Alzheimer's disease
(AD) includes a long latent phase, referred to as preclinical AD, which precedes the onset of …

Technologies for imaging the pathophysiology of Alzheimer disease (AD) now permit
studies of the relationships between the two major proteins deposited in this disease …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Virtually all adults with Down syndrome (DS) show the neuropathological changes of
Alzheimer disease (AD) by the age of 40 years. This association is partially due to …

Most neurodegenerative disorders are associated with aggregated protein deposits. In the
case of Alzheimer disease (AD), extracellular amyloid-β (Aβ) aggregates and intracellular …

Objectives: To estimate a regional progression pattern of amyloid deposition from cross-
sectional amyloid-sensitive PET data and evaluate its potential for in vivo staging of an …

Although amyloid imaging with PiB-PET ([C-11] Pittsburgh Compound-B positron emission
tomography), and now with F-18-labeled tracers, has produced remarkably consistent …

Background The order and magnitude of pathologic processes in Alzheimer's disease are
not well understood, partly because the disease develops over many years. Autosomal …

The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years
before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a …

Major imaging biomarkers of Alzheimer's disease include amyloid deposition [imaged with
[11C] Pittsburgh compound B (PiB) PET], altered glucose metabolism (imaged with [18F] …